抄録
Genetic information, which is useful for understanding and describing large interindividual differences in the pharmacokinetics and pharmacodynamics of clinically useful drugs, is continuously increasing. Genetic polymorphism in drug metabolizing enzymes and drug transporters has been focused on currently, especially for cytochrome P-450s (CYPs, such as CYP2C9, CYP2C19, and CYP2D6), and organic anion transporting polypeptides 1B1(OATP1B1)and pglycoprotein, respectively, are available in various clinical situations. Currently in Japan, pharmacogenomic(PGx)observations are incorporated into drug labels(for various types of drugs such as proton pump inhibitors(PPIs), anti-cancer drugs and NSAIDs), highly advanced medical technology(e. g., CYP2C19 genotyping for eradication of H. pylori by PPIs), and national healthcare insurance for the genotyping test(e. g., UGT1A1 genotyping in irinotecan therapy). Nevertheless, the clinical uptake of PGx knowledge has been limited. Concise and reproducible evidences, the genotyping cost, and education of PGx utility for medical staffs should be considered for the future medicine.
